• Abaloparatide increases BMD, improves bone turnover markers in men with osteoporosis

    8 days ago - By Healio

    SAN DIEGO - Men with osteoporosis receiving daily injections of abaloparatide had greater increases in bone mineral density at the lumbar spine, total hip and femoral neck at 12 months compared with placebo, according to a speaker.
    As Healio previously reported, abaloparatide was approved by the FDA in April 2017 for the treatment of postmenopausal women with osteoporosis and a high risk for fractures. In new findings from a phase 3 study presented at the AACE Annual Scientific and Clinical Conference, abaloparatide was associated with improvements in BMD and in
    Read more ...